Intestinal secretion rates of albumin, hyaluronan, and beta2-microglobulin (beta2-micro) were determined under basal conditions and after gliadin challenge of coeliac patients and healthy controls by the use of a jejunal perfusion technique. A new tube system was used where a jejunal segment is isolated between balloons and then perfused with a balanced salt solution. Under basal conditions the secretion rate of albumin was similar in the patients and controls while the secretion rate of the glycosaminoglycan hyaluronan, a high molecular weight connective tissue component, was increased more than two times in coeliac patients. Beta2-micro was secreted in on average three-fold rates in coeliacs compared with controls. All three substances were secreted at a higher rate in patients with active disease than in those with inactive disease defined by morphological damage in small bowel biopsies. The concentrations in jejunal perfusion fluids relative to serum levels in the coeliac patients were for albumin 0.0007, beta2-micro 0-10, and for hyaluronan 1-94. Challenge with a single dose of gliadin into the jejunal segment gave within 60 min a significant, about two-fold, increase of the secretion rates of all three measured substances. The appearance of hyaluronan could reflect a gliadin induced mucosal oedema with an enhanced leakage from the interstitial/lymph fluid, rich in this glycosaminoglycan. The observed parallel increases in the jejunal secretion of albumin and beta2-micro after gliadin challenge are best explained by a similar mechanism.
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Inflammatory affection of the mucosa might influence the leakage from the capillary bed/ interstitial fluid to the bowel lumen. The aim of this study was to elucidate this possibility by continuous measurements of the intestinal appearance of substances from plasma and/or lymph fluid under basal conditions and after local gliadin challenge of a perfused jejunal segment. This was made possible by the use of a recently developed multichannel tube with two occluding balloons allowing measurement of the secretion in an isolated small bowel segment.7 In this study we report the jejunal appearance rates of low and high molecular weight substances; albumin, beta2-microglobulin (beta2-micro), and hyaluronan. The tube was introduced orally after local anaesthesia with lignocaine. A Teflon coated guide wire was used during insertion of the tube. The tube was positioned with fluoroscopic control, with the segment for perfusion in the proximal jejunum. Air was inflated into the balloons and the isolated segment was rinsed with isotonic saline. The cleaning of the segment was continued for 30 minutes or until the recovered fluid was visually clean. The volume of the isolated bowel segment was experimentally found to be 80-100 ml. A separate standard gastric tube was positioned in the stomach for continuous drainage of gastric secretions through suction. After the rinsing period, the segment was perfused at 3 ml/min with a solution containing 10 mmol glucose, 5 4 mmol KC1, 120 mmol NaCl, 2 mmol Na2HPO4, 1 g/l polyethylene glycol (PEG) 4000, and 35 mmol mannitol. '4C-labelled PEG (Mw 4000 daltons, 2-5 [tCi/l; Amersham, Buckinghamshire, England) was added to the perfusion fluid as a volume marker. Aprotinin (10000 KIU/ml; Bayer AG, Leverkusen FRG) was added to the perfusion fluid, 10 ml/l, to inhibit possible proteolytic activity in the perfused segment. Phenol red solution (50 mg/l saline) was infused proximally to the first balloon at a rate of 1 ml/ min and analysed in the effluent from the intestinal segment. All solutions infused were 37°C. The jejunal perfusion fluid was collected by gravity drainage. The perfusion fluids were collected on ice and were fractionated in 20 min samples. The fluids were frozen at -70°C in small samples of 1-2 ml pending analysis. The patients were recumbent during the whole perfusion period of 160-180 min. All patients were examined after an overnight fast. The mean recovery of 14C-PEG 4000 during perfusion was 94%, range 83-100. The mean leakage of phenol red to the segment was <2%, range < 1-3. In order to further assure that contamination of the effluent from pancreatic secretion did not occur, the trypsin content of the effluent was measured, using N-p-tosyl-L-arginine methylesther (TAME) as substrate, and determined spectrophotometrically at 247 nm. ' concentration in perfusion fluid x 3 ml/min x 60 min/ 0 cm= amount/cm intestine/hour. The study was approved by the Ethical Committee of the Medical Faculty, Uppsala University. Patients and controls gave their informed consent to participation in the study.
Results
The concentrations of beta2-microglobulin (beta2-micro), albumin, and hyaluronan in jejunal perfusion fluid from patients with coeliac disease and controls are given in Table II were calculated (Table II) . The differences observed between the groups were not influenced by this calculation. Those patients who had active coeliac disease defined by histological findings on biopsy presented higher appearance rates ofall substances, but the differences did not reach statistical significance (Table III) . The serum concentrations of albumin and hyaluronan in the coeliac group were 43 (0-7) (SEM) g/l and 44 5 (8 8) [tg/l, respectively, and within the reference values at our laboratory; the normal range for albumin being 36-48 g/l and for HA 10-100 [tg/l. The serum beta2-micro values tended to be slightly increased in the patient group, 1 -8 (0 1) mg/l; the reference value at our laboratory is 1 1-2 1 mg/l. The ratios between the serum and jejunal fluid concentrations in the patients group were for beta2-micro 0-10, for albumin 0 0007 and for hyaluronan 1-94. During challenge with gliadin the appearance rates of beta2-micro, albumin and hyaluronan started to increase at the same time and on average 40 minutes after administration of gliadin (Figs 2, 3) . A tendency towards an earlier onset of the influx of beta2-micro was observed. The peak appearance rates of the measured variables were on average twice as high, compared with basal appearance rates, and reached a maximum 60 minutes after gliadin administration. The enhanced appearance rates of hyaluronan and albumin levelled off after that time but remained raised during the observation period of 120 minutes after the gliadin challenge. In contrast, the appearance rate of beta2-micro started to decrease after 60 min and returned to basal levels within the 120 min observation period (Fig 2) . Gliadin challenge tests of healthy controls did not alter the appearance rates of the measured substances (data not shown). Among the coeliac patients the maximum appearance rates varied within narrow limits (Fig 4) . The maximum increases, in absolute or relative terms, were apparently not related to differences in the histopathological activity of the disease.
Only two of the patients had minor subjective reactions during gliadin challenge. One propose that the increased serum concentrations of beta2-micro in coeliac disease might at least partly reflect an enhanced production of this protein in the intestine. All nucleated cells are able to synthesise beta2-micro. An increased production of beta2-micro in the mucosa may reflect the increased enterocyte turnover which has been documented to be greatly enhanced in coeliac disease." An alternative explanation could be an increased production from invading cells, mainly lymphocytes.24 Beta2-microroglobulin is a low molecular weight substance (Mw 11800 daltons) and should appear more easily than albumin in the intestinal fluid. It was also calculated that the ratio between the concentration of beta2-micro in jejunal fluid in relation to serum levels was relatively higher in healthy controls than the corresponding ratio for albumin. The appearance rate of beta2-micro was on average doubled after gliadin challenge of coeliac patients. The increased influx of beta2-micro tended to precede the increased influxes of albumin and hyaluronan. Furthermore, in contrast with these substances, the enhanced appearance of beta2-micro was transient and at the end of the 120 min follow up period after gliadin administration, its appearance rate had returned to basal levels. These differences in the behaviour of the measured variables can possibly be explained if we assume that the leakage from the tissue is a transient phenomenon in our gliadin challenge model. In such a situation, differences in molecular sizes of the leaking substances might influence the kinetics of their transport to the jejunal lumen. Alternatively the rapid increase and decrease of beta2-micro could reflect the local tissue damage elicited by the gliadin challenge. Enterocyte damage has been reported to occur within two hours.46
In conclusion, we have shown that a very transient challenge of the small bowel with gliadin induces an increase in the appearance rates of beta2-micro, albumin, and hyaluronan in patients with coeliac disease but not in healthy controls. The appearance of these substances in increased amounts in the jejunal fluid points to a gliadin induced lymphoedema and an enhanced leakage fromt he interstitial/lymph fluid. The perfusion technique used allows kinetic studies of the local intestinal reactions mediated by gliadin and it restricts the gliadin challenge in dose, time, and intestinal area. 
